COMPARISON OF NK-2 SELECTIVE PEPTIDE AND NONPEPTIDE ANTAGONISTS IN RAT DISTAL COLON MUSCULARIS MUCOSAE

被引:3
作者
ASTOLFI, M [1 ]
MANZINI, S [1 ]
MAGGI, CA [1 ]
GIACHETTI, A [1 ]
机构
[1] A MENARINI PHARMACEUT,DEPT PHARMACOL,FLORENCE,ITALY
来源
JOURNAL OF AUTONOMIC PHARMACOLOGY | 1993年 / 13卷 / 06期
关键词
D O I
10.1111/j.1474-8673.1993.tb00285.x
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
1 The effects of natural and synthetic tachykinin agonists as well as those of peptide (linear and cyclic) and non-peptide NK-2 antagonists have been assessed in the rat colon muscularis mucosae (RCMM). 2 The rank order of agonist potency was neurokinin A (NKA)>ArgNKB > > Substance P (SP). The selective NK-2 agonist [betaAla8]NKA(4-10) had an intrinsic activity similar to NKA, while [MePhe7]NKB (NK-3 selective) and [Pro9] substance P (SP) sulphone (NK-1 selective) had slight and no motor activity, respectively. 3 All the antagonists produced a concentration-dependent rightward shift of the cumulative concentration-response curve to NKA. The following rank order of affinity was obtained: SR 48968>L659,877>MEN 10376>R396. 4 The antagonism exerted by peptide antagonists (L659,877, MEN 10376 and R396) was unaffected by lengthening of the incubation time or presence of peptidase inhibitors. 5 The pseudopeptide, MDL 28,564, behaved as a weak antagonist. 6 These findings indicate that NK-2 receptors are the main, if not the sole, mediators of tachykinin-induced motor effects in RCMM. The rank order of potency of peptide antagonists, as well as the antagonistic properties of the pseudopeptide MDL 28,564, suggest the existence of preferential expression of NK-2B receptors in RCMM.
引用
收藏
页码:381 / 386
页数:6
相关论文
共 20 条
[1]   RELATIVE POTENCIES OF NEUROKININS IN GUINEA-PIG TRACHEA AND HUMAN BRONCHUS [J].
ADVENIER, C ;
NALINE, E ;
DRAPEAU, G ;
REGOLI, D .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 139 (02) :133-137
[2]   A STUDY OF [D-PRO2,D-PHE7,D-TRP9]-SUBSTANCE-P AND [D-TRP7,9]-SUBSTANCE P AS TACHYKININ PARTIAL AGONISTS IN THE RAT COLON [J].
BAILEY, SJ ;
JORDAN, CC .
BRITISH JOURNAL OF PHARMACOLOGY, 1984, 82 (02) :441-451
[3]   CONCEPTS IN CHARACTERIZATION OF TACHYKININ RECEPTORS [J].
BURCHER, E ;
MUSSAP, CJ ;
GERAGHTY, DP ;
MCCLURESHARP, JM ;
WATKINS, DJ .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1991, 632 :123-126
[4]   SELECTIVE AGONISTS FOR SUBSTANCE-P AND NEUROKININ RECEPTORS [J].
DRAPEAU, G ;
DORLEANSJUSTE, P ;
DION, S ;
RHALEB, NE ;
ROUISSI, NE ;
REGOLI, D .
NEUROPEPTIDES, 1987, 10 (01) :43-54
[5]  
EMONDSALT X, 1992, LIFE SCI, V50, P101
[6]  
HAGAN RM, 1989, BRIT J PHARMACOL, V98, P717
[7]  
HARBESON SL, 1990, PEPTIDES CHEM STRUCT, P180
[8]  
MAGGI CA, 1991, J PHARMACOL EXP THER, V257, P1172
[9]   THE HAMSTER ISOLATED TRACHEA - A NEW PREPARATION FOR STUDYING NK-2 RECEPTORS [J].
MAGGI, CA ;
PATACCHINI, R ;
ROVERO, P ;
MELI, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 166 (03) :435-440
[10]   INVIVO AND INVITRO PHARMACOLOGY OF SR-48,968, A NONPEPTIDE TACHYKININ NK2 RECEPTOR ANTAGONIST [J].
MAGGI, CA ;
PATACCHINI, R ;
GIULIANI, S ;
GIACHETTI, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 234 (01) :83-90